“Study of a novel drug for the familial episodic infantile limb pain syndrome” was chosen by AMED as Cyclic Innovation for Clinical Empowerment (CiCLE) program and was initiated collaboratively with Kyoto University and Akita University.
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada; hereinafter referred to as “AlphaNavi Pharma”) announced that it have begun the study of a novel drug for the familial episodic infantile limb pain syndrome with Kyoto University and Akita University, chosen as one program of the Cyclic Innovation for Clinical Empowerment (CiCLE) by the Japan Agency for Medical Research and Development (AMED).
AlphaNavi Pharma is developing the selective voltage-gated sodium channel (Nav) inhibitor, ANP-230 for the treatment-resistant rare pain disease, the familial episodic infantile limb pain syndrome, which was recently clarified to be caused by some voltage-gated sodium channel (Nav) gene mutations, worked closely with Kyoto University and Akita University. From now on, Akita University (Professor Tsutomu Takahashi) will conduct genetic epidemiology study for that disease and Kyoto University (Associated professor Kouji Harada) will implement the Nav gene mutation analysis and functional assay. Collaborated with them, AlphaNavi will plan to implement a Ph1/2 study of ANP-230 for the familial episodic infantile limb pain syndrome.
About the Cyclic Innovation for Clinical Empowerment (CiCLE)
As a project of the Japan Agency for Medical Research and Development (AMED), the Cyclic Innovation for Clinical Empowerment (CiCLE) aims to formulate an innovative infrastructure (including human resources) for accelerating promotion of research and development and practical use of drug discovery activity outcomes in ways that precisely match the needs of medical professionals, and to create an environment in which development of open innovation ventures in medical research and development is empowered by uniting Japan’s collective strengths through industry-university-government cooperation.
About AlphaNavi Pharma Inc.,
AlphaNavi was established as a start-up company in January 2019, whose mission is to develop a novel analgesic drug for patients suffering from pain, their families, and medical professionals as soon as possible and to regain the smiles of patients and their families. In addition to the research for voltage-gated sodium channel (Nav)-mutated rare pain diseases, AlphaNavi Pharma is developing a selective Nav inhibitor, ANP-230, to cure pain diseases.